The Effects of Disease‐Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis

Xia Zhang, Shuang Song, Bo Chen, Letizia Leocani, Xingyu Zhao, Yong Zhong, Marco Pisa, Srilakshmi M. SharmaEuropean 2025 · DOI

TL;DR

This study systematically reviewed and analyzed data from 21 studies to assess how disease-modifying therapies (DMTs) impact optic nerve degeneration in multiple sclerosis (MS) patients. The findings suggest that high-efficacy DMTs are more effective than moderate-efficacy DMTs in slowing down the thinning of the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL), with GCIPL showing particular promise as a sensitive biomarker for monitoring disease progression and treatment efficacy.

What Problem Does This Paper Address?

Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system, leading to progressive neurodegeneration that contributes to long-term disability. While the optic nerve is often affected, and its degeneration is linked to visual and overall disability, reliably monitoring this specific aspect of MS progression and the effectiveness of treatments has been challenging. Optical coherence tomography (OCT) offers a non-invasive way to measure the thickness of the retinal nerve fiber layer (RNFL) and the ganglion cell-inner plexiform layer (GCIPL), which are proxies for neuroaxonal loss in the optic nerve. However, there's been a lack of clear consensus on how different types of disease-modifying therapies (DMTs) – the standard treatment for MS – impact these OCT measures, and whether one type of therapy is superior to another in preserving optic nerve health. This paper aims to fill that gap by systematically reviewing and meta-analyzing existing research to provide a clearer picture of DMT efficacy on optic nerve degeneration.

Methods

The researchers conducted a systematic review and meta-analysis following the PRISMA guidelines. They searched multiple databases (Ovid Medline, Ovid Embase, PubMed, Web of Science, CINAHL) for studies published up to April 2023 that reported longitudinal OCT data on RNFL and GCIPL thickness in MS patients undergoing DMT treatment.

Key methodological aspects include:

  • Inclusion Criteria: Studies needed to include patients with MS diagnosed by current criteria, aged 18+, with longitudinal OCT data on DMT treatment, and reporting RNFL/GCIPL thickness at baseline and follow-up (at least 1 year). Studies with specific exclusion criteria (e.g., recent optic neuritis, ocular/systemic comorbidities affecting OCT, specific OCT devices) were excluded.
  • DMT Classification: DMTs were categorized into moderate-efficacy (M-DMTs) and high-efficacy (H-DMTs) therapies.
  • Primary Outcome: The primary effect size measure was the standardized mean difference (Hedges' g) of annualized RNFL and GCIPL thinning between baseline and follow-up.
  • Statistical Analysis: A meta-analysis was performed using the 'metafor' package in R. Moderation analyses were conducted to explore the influence of covariates like age, sex, disease duration, and OCT device.

Datasets

The study did not introduce new datasets. Instead, it synthesized data from 21 previously published studies that met the inclusion criteria. These studies collectively included 2158 patients and 3685 eyes. The data extracted from these studies comprised longitudinal OCT measurements of RNFL and GCIPL thickness, along with patient demographic and clinical information.

Key Insights and Ideas

  • GCIPL as a Superior Biomarker: The study strongly suggests that GCIPL thinning is a more sensitive indicator of optic nerve damage in MS than RNFL thinning. This is attributed to the methodological approach of measuring macular GCIPL thickness, which is more comprehensive than RNFL measurements.
  • H-DMTs Offer Greater Protection: High-efficacy DMTs demonstrated a more significant effect in reducing longitudinal thinning of both RNFL and GCIPL compared to moderate-efficacy DMTs. This implies a neuroprotective benefit of more potent MS treatments.
  • DMTs Slow Down Degeneration: Overall, the meta-analysis confirmed that MS patients treated with DMTs experience significant annualized thinning of RNFL and GCIPL, but the rate of thinning is demonstrably slower with H-DMTs.
  • Subgroup Analysis Limitations: While the study attempted subgroup analyses for different MS subtypes (RRMS vs. PMS) and history of optic neuritis, the limited number of studies available for some analyses (e.g., PMS, ON history) restricted definitive conclusions.

Key Results

  • Overall Thinning: A significant annualized RNFL thinning (g = -0.6715, p = 0.0077) and GCIPL thinning (g = -0.3072, p < 0.0001) was observed across all included studies compared to baseline.
  • M-DMTs vs. H-DMTs:
    • RNFL: Significant thinning was observed in the M-DMT group (g = -0.6992, p = 0.0243), but not significantly in the H-DMT group (g = -0.6249, p = 0.1062). However, the difference in thinning rates between M-DMTs and H-DMTs was not statistically significant (p = 0.87).
  • GCIPL: Significant thinning was observed in both M-DMTs (g = -0.3816, p = 0.0006) and H-DMTs (g = -0.1860, p < 0.0001) groups. Crucially, GCIPL thinning was significantly greater in the M-DMT group compared to the H-DMT group (g = -0.20, p = 0.0017), indicating H-DMTs are more effective at preventing GCIPL thinning.
  • Subgroup Findings: No significant difference in annualized RNFL thinning was observed between RRMS and PMS groups, nor between eyes with or without a history of optic neuritis.

Limitations and Future Work

  • Limitations:
    • Data Availability and Quality: The study acknowledges potential bias due to the availability and quality of published data. While efforts were made to ensure data integrity, some studies had incomplete reporting, necessitating statistical adjustments.
  • Heterogeneity: While overall heterogeneity was minimal, variations in standard deviations across studies were noted.
  • Limited Sample Size for Subgroups: The number of studies available for specific subgroup analyses (e.g., PMS, ON history) was limited, potentially reducing statistical power and obscuring significant findings.
  • DMT Classification: The majority of M-DMT studies used interferons, and newer M-DMT options were not represented in the included studies. Similarly, few H-DMTs were available for PMS patients.
  • N-DMT Cohort Size: The meta-analysis of untreated/placebo groups was based on only six cohorts, which may have limited the power to detect differences in RNFL thinning rates.
  • Future Work:
    • Prospective Studies and RCTs: The authors emphasize the need for further prospective studies and randomized controlled trials (RCTs) to refine therapeutic strategies and enhance patient care by specifically addressing the impact of different DMTs on RNFL and GCIPL degeneration.
  • Focus on PMS: More attention should be devoted to the optic structural changes in people with progressive MS (PwPMS) receiving treatment, as responsiveness to DMTs may differ.
  • Investigating N-DMTs: Further research into OCT thinning in MS cohorts without DMT treatment could help explore the influence of clinical and demographic variables on retinal thinning rates.
  • GCIPL as a Biomarker: The study strongly advocates for the use of GCIPL thinning as a sensitive predictor for monitoring optic nerve degeneration and assessing DMT efficacy in both RRMS and PMS.

Summary updated

Abstract

High-DMTs are more effective in reducing longitudinal thinning of RNFL and GCIPL compared with M-DMTs. GCIPL thinning could serve as a sensitive predictor for the surveillance of optic nerve degeneration and the assessment of DMT efficacy for both RRMS and PMS.
BibTeX
@inproceedings{zhang2025effects,
  author = {Xia Zhang and Shuang Song and Bo Chen and Letizia Leocani and Xingyu Zhao and Yong Zhong and Marco Pisa and Srilakshmi M. Sharma},
  title = {{The Effects of Disease‐Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis}},
  booktitle = {European},
  year = {2025},
  doi = {10.1111/ene.70081},
}
Figure